Showing results (831-840 of 842) with videos related to

Sort By:
Pageof 85
Science (New York, N.Y.)|January 29, 1999
Reduced immunotoxicity and preservation of antibacterial activity in a releasable side-chain carbapenem antibioticH Rosen, R Hajdu, L Silver, et al.
Nature Communications|March 28, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II studyFilipa Lynce, Candace Mainor, Renee N Donahue, et al.
Science Advances|September 20, 2023
Intentional creation of carbon-rich dark earth soils in the AmazonMorgan J Schmidt, Samuel L Goldberg, Michael Heckenberger, et al.
MMWR. Morbidity and Mortality Weekly Report|March 7, 2014
Notes from the field: rapidly growing nontuberculous Mycobacterium wound infections among medical tourists undergoing cosmetic surgeries in the Dominican Republic--multiple states, March 2013-February 2014David Schnabel, Joanna Gaines, Duc B Nguyen, et al.
Nucleic Acids Research|October 29, 2013
Ensembl Genomes 2013: scaling up access to genome-wide dataPaul Julian Kersey, James E Allen, Mikkel Christensen, et al.
Nature Communications|October 7, 2024
Transcript errors generate amyloid-like proteins in huwman cellsClaire S Chung, Yi Kou, Sarah J Shemtov, et al.
Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science|February 21, 2014
Comprehensive laboratory evaluation of a specific lateral flow assay for the presumptive identification of abrin in suspicious white powders and environmental samplesJason G Ramage, Kristin Willner Prentice, Stephen A Morse, et al.
The Journal of Infectious Diseases|May 2, 2013
Safety of zoster vaccine in elderly adults following documented herpes zosterVicki A Morrison, Michael N Oxman, Myron J Levin, et al.
Frontiers in Immunology|June 4, 2026
Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet)Ajay Bansal, Elena M Stoffel, Ramona Lim, et al.
Pageof 85